This medication has a combination of two active ingredients Zidovudine / Lamivudine. Zidovudine is a synthetic dideoxynucleoside that inhibits DNA polymerase, leading to the inhibition of DNA replication and cell death. This active ingredient also reduces levels of available pyrimidines. It is a nucleoside analog and reverses transcriptase inhibitor indicated in combination with other drugs in the therapy and prophylaxis of the human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS).
Lamivudine is a synthetic nucleoside analog with activity against hepatitis B virus and HIV. This medication is phosphorylated to its active metabolites. In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) through DNA chain termination after incorporation of the nucleoside analog into viral DNA. In HBV, the incorporation of L-MP into viral DNA by HBV polymerase leads to DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase.
The combination of two medications lamivudine and zidovudine is indicated with other HIV drugs to help control HIV infection. Combivir helps to decrease the amount of HIV in the body so the immune system can work better. It lowers the risk of getting HIV complications like new infections, and cancer and improves the quality of life. This drug belongs to a group of drugs known as nucleoside reverse transcriptase inhibitors.
Given medication acts by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to reproduce itself in the cells it has infected. Combivir is a combination of two active ingredients. It reduces the amount of HIV in the blood and keeps it at a low level.
This medicine is made available in a dosage as mentioned below:
- 150 mg + 300 mg: It is to be administered orally exactly as mentioned in the prescription by the doctor
This drug can weaken the immune system and cause signs of infection like fever, mouth sores, skin sores, flu symptoms, and pale skin.